CANN
GROUP LIMITED

ASX ANNOUNCEMENT

NAB Facilities – Expiry Extension

1 October 2025 – Cann Group Limited ("Cann" or the "Company") advises that it has received notice of a short-term extension from National Australia Bank (NAB) advising that the expiry dates of all NAB debt facilities (construction loan and working capital facility) have been extended from 30 September 2025 until 15 October 2025. All other terms and conditions of the facilities remain unchanged.

The Company and its lenders continue to collaborate on restructuring Cann's debt arrangements, with this extension expected to allow sufficient time for Cann to substantially progress its refinancing initiatives which were outlined in its recent 2025 Annual Report.

Authorised for release by the Board of Directors, Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

About Cann Group
Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouplimited.com | www.satipharm.com